Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis

CNS Drugs
Marita ZimmermannJosh J Carlson

Abstract

Several disease-modifying therapies (DMTs) treat relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Few comprehensive cost-effectiveness analyses exist in this area, particularly from a payer perspective, despite rapidly increasing prices of DMTs. We aimed to systematically compare cost effectiveness of all relevant DMTs for first-line treatment of RRMS, second-line treatment of RRMS, and first-line treatment of PPMS. We used a Markov model with health states based on Expanded Disability Status Score categories. Upon discontinuing first-line treatment, RRMS patients continued to second-line therapy then to supportive care, and PPMS patients moved directly to supportive care. Data was sourced from clinical trials and commercially and publicly available sources. The target population was treatment-naïve adults with RRMS or PPMS. We used a lifetime horizon from a US payer perspective, and compared DMTs for RRMS (first-line: dimethyl fumarate, glatiramer acetate, interferon β-1a, interferon β-1b, peginterferon β-1a, teriflunomide, natalizumab, fingolimod, and ocrelizumab; second-line: alemtuzumab, natalizumab, fingolimod, and ocrelizumab), ocrelizumab for PPMS, and supportive care. Outc...Continue Reading

References

Feb 15, 2008·The New England Journal of Medicine·Stephen L HauserUNKNOWN HERMES Trial Group
Jun 11, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Paul TappendenMurray Brown
Jul 21, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·N PutzkiV Limmroth
Dec 10, 2009·Neurology·Marcus KochHelen Tremlett
Jan 6, 2012·The Patient·Merrikay Oleen-BurkeyKenneth P Johnson
Jun 29, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Bernd C Kieseier, Carlo Pozzilli
Sep 21, 2012·The New England Journal of Medicine·Robert J FoxUNKNOWN CONFIRM Study Investigators
Sep 21, 2012·The New England Journal of Medicine·Ralf GoldUNKNOWN DEFINE Study Investigators
May 21, 2013·Annals of Neurology·Omar KhanUNKNOWN GALA Study Group
Feb 11, 2014·Handbook of Clinical Neurology·Douglas S Goodin
May 27, 2015·Multiple Sclerosis and Related Disorders·Molly NickersonRuth Ann Marrie
Aug 6, 2015·World Journal of Clinical Cases·Alberto Gajofatto, Maria Donata Benedetti
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·G FurneriL G Mantovani
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·J Olsen, A Wiren
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·M RaikouG Rombopoulos
Dec 22, 2016·The New England Journal of Medicine·Xavier MontalbanUNKNOWN ORATORIO Clinical Investigators
Apr 30, 2017·Nature Reviews. Drug Discovery·Asher Mullard
Aug 25, 2017·Neurology·Eva HavrdovaUNKNOWN CARE-MS I and CAMMS03409 Investigators
Apr 11, 2018·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Carlo PiccinniNello Martini

❮ Previous
Next ❯

Citations

Jan 4, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Jonas GrafHans-Peter Hartung
May 16, 2019·Expert Opinion on Pharmacotherapy·Emanuele D'AmicoFrancesco Patti
Nov 12, 2020·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Ingrid E H KremerNick Bansback
Jan 12, 2021·Multiple Sclerosis and Related Disorders·N PoudelS Ngorsuraches
Jan 22, 2021·Expert Review of Pharmacoeconomics & Outcomes Research·Surachat Ngorsuraches, Nabin Poudel
Feb 17, 2021·Multiple Sclerosis and Related Disorders·Mohaddeseh H GoudarziSamantha A Hollingworth
Jul 10, 2020·Multiple Sclerosis and Related Disorders·David BakerKlaus Schmierer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.